SHANGHAI OPM BIOSCIENCES CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.58 CNY | +0.62% |
|
-6.34% | -35.51% |
| 09/05 | OPM Biosciences' Shareholder to Cut Stake | MT |
| 29/04 | Shanghai OPM Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2024 * | 35Cr 4.79Cr 400.23Cr | Sales 2025 * | 50Cr 6.89Cr 575.7Cr | Capitalization | 405.31Cr 56Cr 4.66TCr |
|---|---|---|---|---|---|
| Net income 2024 * | 8.9Cr 1.23Cr 102.4Cr | Net income 2025 * | 15Cr 2.07Cr 172.59Cr | EV / Sales 2024 * | 11.7 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 8.1 x |
| P/E ratio 2024 * |
45.6
x | P/E ratio 2025 * |
27.2
x | Employees | 285 |
| Yield 2024 * |
0.93% | Yield 2025 * |
2.08% | Free-Float | 25.54% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.62% | ||
| 1 week | -6.34% | ||
| Current month | -5.65% | ||
| 1 month | -6.37% | ||
| 3 months | -11.89% | ||
| 6 months | -33.06% | ||
| Current year | -35.51% |
1 week
34.42
38.27
1 month
34.4242.43
Current year
29.6756.08
1 year
29.6764.64
3 years
29.6798.56
5 years
29.6798.56
10 years
29.6798.56
| Managers | Title | Age | Since |
|---|---|---|---|
Zhi Hua Xiao
CEO | Chief Executive Officer | 50 | 27/13/27 |
Liang Ping Ni
DFI | Director of Finance/CFO | 40 | 01/19/01 |
Chuan Yang Guo
BRD | Director/Board Member | 36 | 01/14/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jiang Feng Li
BRD | Director/Board Member | 47 | 12/20/12 |
Zhi Hua Xiao
CEO | Chief Executive Officer | 50 | 27/13/27 |
Jun Jie Zhang
BRD | Director/Board Member | 47 | 14/20/14 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/24/21 | 35.58 | +0.62% | 357,367 |
| 20/24/20 | 35.36 | +0.17% | 505,836 |
| 19/24/19 | 35.3 | -0.59% | 280,649 |
| 18/24/18 | 35.51 | -3.32% | 832,731 |
| 17/24/17 | 36.73 | -3.32% | 871,174 |
End-of-day quote Shanghai S.E., June 21, 2024
More quotes
Shanghai OPM Biosciences Co Ltd is a China-based company mainly engaged in cell culture products and services. The Company's main business involves two application areas: cell culture medium series products and biopharmaceutical contract development and production services. The Company's cell culture medium series products are widely used in the production of biological products such as protein/antibody production, vaccine production, cell therapy/gene therapy, and others. The Company's antibody drug development contract development and manufacturing organization (CDMO) service platform is committed to providing domestic and foreign customers with full-process services from antibody engineering humanization screening, cell line construction, process development to pilot production and clinical I&II phase sample production.
Sector
Pharmaceuticals
Calendar
21/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
35.58
CNY
Average target price
53.41
CNY
Spread / Average Target
+50.11%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -35.51% | 56Cr | |
| +2.22% | 9.39TCr | |
| -1.32% | 3.84TCr | |
| -13.44% | 3.26TCr | |
| +76.30% | 2.82TCr | |
| -13.11% | 1.59TCr | |
| +0.68% | 1.42TCr | |
| -12.06% | 1.15TCr | |
| +185.28% | 1.07TCr | |
| -53.00% | 946.85Cr |
- Stock Market
- Equities
- 688293 Stock
